While South Africa may have been lucky to get access to the Johnson & Johnson vaccine quickly, some issues remain, writes Neil Stacey. South Africa’s vaccine rollout got underway last week, using the single-dose Johnson & Johnson vaccine, just three weeks after the release of Phase 3 efficacy trial results for that vaccine, a truly remarkable turnaround time. As lucky as we have gotten with the Johnson & Johnson arrangement, some issues remain. This figure can’t be directly compared to the 57% reported by Johnson & Johnson, because they measure quite different things. Essentially, by reporting on efficacy against higher severities of illness, Johnson & Johnson have measured themselves against different goalposts than AstraZeneca did.

Source: News 24 February 23, 2021 03:11 UTC